(Press-News.org) CHICAGO --- A phase II clinical trial of the first new type of drug for musculoskeletal pain since aspirin shows that it significantly reduces knee pain in osteoarthritis, the most common osteoarthritis pain, according to new research from Northwestern Medicine.
However, phase III trials of that drug, tanezumab, have been placed on clinical hold after 16 out of several thousand participants in the new trial developed progressively worsening arthritis and bone changes that required total joint replacements.
"The bottom line is this is a very effective drug for relieving pain; unfortunately, it appears some people go on to have their osteoarthritis progress more quickly," said Thomas Schnitzer, M.D., a rheumatologist and professor in the department of physical medicine and rehabilitation at Northwestern Medicine. "The long-term safety of tanezumab needs to be better understood."
Schnitzer is a principal investigator and lead author of a paper on the research, which will be published Aug. 26 in the New England Journal of Medicine. He also was an investigator on the phase III trial. The other lead author and principal investigator is Nancy Lane, M.D., a professor of internal medicine at UC Davis School of Medicine.
Tanezumab is the first new drug for general muscle or joint pain in over 100 years, Schnitzer said, noting nonsteroidals and COX inhibitors are a "fancy form of aspirin."
"It's very exciting to have a new approach to manage pain for osteoarthritis," he said.
Other drugs currently used to treat pain have significant side effects -- bleeding, ulcers and an increase in heart attacks -- that limit their use.
Anecdotally, tanezumab appears to provide greater pain relief than current drugs.
"The effects of tanezumab were remarkable," Lane said. "People on the drug went from having very limited activity to practically being on the dance floor. No medication available today has such dramatic results."
Schnitzer and Lane said the apparent worsening of certain patients' condition could be because tanezumab helped patients increase their activity and, as a result, put more stress on their diseased joints.
In the phase II study of 440 patients, treatment with tanezumab reduced knee pain during walking by 45 to 62 percent compared to 22 percent reduction in pain with a placebo. The pain scores were equal to or lower than those reported by patients during screening while taking their prior pain medication.
Schnitzer said the Food and Drug Administration (FDA) is examining data to decide how to proceed.
"The FDA may decide it's too dangerous overall or, rather, that there may be a specific patient population in which it should not be used or who need to be warned about possible serious side effects," he said.
The drug works by neutralizing or blocking Nerve Growth Factor (NGF), a molecule needed for normal development of the nervous system, but which also gets released when there is inflammation in the body. NGF stimulates nerve cells and triggers pain.
Nearly 27 million adults in the United States have osteoarthritis, according to the U.S. Department of Commerce, and about 40 percent suffer from knee osteoarthritis. The number of people with osteoarthritis is expected to rise as baby boomers reach retirement age and as the number of obese Americans increases. Half of all adults will develop symptoms in the knee at some point in their lives.
INFORMATION:
The research was funded by Rinat Neuroscience Corporation, now a subsidiary
of Pfizer Inc. Schnitzer has received consulting fees from Logical Therapeutics,
Horizon Therapeutics, Merck, NicOx, Winston Laboratories, Solstice and
Santosolve; performs clinical research for Genzyme, Eli Lilly, Pfizer, Nordic
Bioscience, Wyeth and Pozen; and holds equity in NicOx.
NORTHWESTERN NEWS: www.northwestern.edu/newscenter/
END
September 29, 2010 ─ (BRONX, NY) ─ A seemingly simple inherited trait – height – springs from hundreds of genetic causes, according to an international team of scientists. Robert Kaplan, Ph.D., professor of epidemiology & population health at Albert Einstein College of Medicine of Yeshiva University, is co-author of a paper on the group's findings published in the September 29 online edition of Nature.
The study identified hundreds of gene variants in at least 180 locations that influence adult height. These results prove that with internet technology it ...
New Haven, Conn.—The rules that govern the world of the very small, quantum mechanics, are known for being bizarre. One of the strangest tenets is something called quantum entanglement, in which two or more objects (such as particles of light, called photons) become inextricably linked, so that measuring certain properties of one object reveals information about the other(s), even if they are separated by thousands of miles. Einstein found the consequences of entanglement so unpalatable he famously dubbed it "spooky action at a distance."
Now a team led by Yale researchers ...
(SACRAMENTO, Calif.) — Just months after a pharmaceutical company halted studies of tanezumab, a drug used in reducing pain and improving function in people with moderate-to-severe osteoarthritis of the knee, the results of a small, phase II clinical trial found only a few minor side effects and substantial improvement in patient conditions. The results of the 16-week study are published in the Sept. 30 issue of The New England Journal of Medicine. Other, longer-term studies have indicated that tanezumab may accelerate osteoarthritis, and the company that manufactures the ...
Research published today provides the first direct evidence that attention-deficit/hyperactivity disorder (ADHD) is a genetic condition. Scientists at Cardiff University found that children with ADHD were more likely to have small segments of their DNA duplicated or missing than other children.
The study also found significant overlap between these segments, known as copy number variants (CNVs), and genetic variants implicated in autism and schizophrenia, proving strong evidence that ADHD is a neurodevelopmental disorder – in other words, that the brains of children ...
A particularly aggressive childhood cancer can be fought successfully with far less chemotherapy than previously believed, avoiding harmful side effects caused by cancer drugs.
The 96 percent survival rate found in an eight-year clinical trial at the University of California, San Francisco, stands to change the approach toward fighting intermediate-risk – stage three and stage four – neuroblastoma. Neuroblastoma attacks the network of cells that control the body's response to stress, known as the sympathetic nervous system, and affects 650 children in the United States ...
Many researchers have studied the relationship between the increase in sales of new antidepressants in recent decades and a simultaneous decline in the suicide rate. In a study based on figures from the Nordic countries, researchers at the Norwegian Institute of Public Health found no evidence that increased sales of the new medicines could be linked to a lower suicide rate. The researchers also did not find any relationship between reduced sales of the older and more toxic antidepressants and a reduction in suicide rates.
The suicide rate has been declining since the ...
Severe sepsis, a disease characterised by a sudden drop in blood pressure and progressive organ dysfunction following infection, remains one of the most common causes of mortality in intensive care units worldwide. Even under the best possible medical conditions, mortality rates range between 30 and 70%. A research team from the Instituto Gulbenkian de Ciência, Portugal, led by Miguel Soares, found that free heme, released from red blood cells during infection, is the cause of organ failure, leading to the lethal outcome of severe sepsis. Moreover this team found that the ...
The key to the stability of any building is its foundation, but it is difficult to test some building sites in advance – such as those on the moon. New research from North Carolina State University is helping resolve the problem by using computer models that can utilize a small sample of soil to answer fundamental questions about how soil at a building site will interact with foundations.
"If you are going to build a large structure, you have to run a lot of tests on the building site to learn how the soil will behave in relation to the building's foundation," says Dr. ...
Athens, Ga. – A new University of Georgia study suggests that mothers who consume a diet high in trans fats double the likelihood that their infants will have high levels of body fat.
Researchers, whose results appear in the early online edition of the European Journal of Clinical Nutrition, found that infants whose mothers consumed more than 4.5 grams of trans fats per day while breastfeeding were twice as likely to have high percentages of body fat, or adiposity, than infants whose mothers consumed less than 4.5 grams per day of trans fats.
The researchers investigated ...
In an advance that may give brewers powerful new ability to engineer the flavor and aroma of beer — the world's favorite alcoholic beverage — scientists are publishing the most comprehensive deciphering of the beer's "proteome" ever reported. Their report on the proteome (the set of proteins that make beer "beer") appears in ACS' monthly Journal of Proteome Research.
Pier Giorgio Righetti and colleagues say they were inspired to do the research by a popular Belgian story, Les Maîtres de l'Orge (The Brew Masters), which chronicles the fortunes of a family of brewers over ...
